Altimmune ends FY2025 with $274M cash; FDA breakthrough for MASH; Phase 3 planned 2026

Altimmune, Inc.

Cash, cash equivalents and short-term investments: $274M at Dec 31, 2025; ~$340M after $75M offering and $8M ATM in Jan 2026.
FY2025 net loss $88.1M ($1.00/share); Q4 net loss $27.4M ($0.27/share).
Pemvidutide granted FDA Breakthrough Therapy Designation for MASH; Phase 3 trial planned in 2026.
Topline data from RECLAIM Phase 2 trial in alcohol use disorder expected Q3 2026.
Jerry Durso appointed CEO; previously CEO of Intercept Pharmaceuticals.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Altimmune, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 5, 2026, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fourth quarter and full year ended December 31, 2025.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-26-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.